title: [Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma].
abstract: Neovascular glaucoma is a serious complication associated with retinal ischemic changes, which increase the production of vascular endothelial growth factor. Vascular endothelial growth factor has been implicated as a key molecule in the development of newly formed vessels and neovascular glaucoma. Intravitreal injection of bevacizumab, a full-length humanized anti-vascular endothelial growth factor monoclonal antibody, leads to a dramatic regression of the new iris and iridocorneal angle vessels on slitlamp examination. However, anterior segment angiography reveals that bevacizumab does not cause a regression of the neovascular vessels themselves but reduces vascular permeability while newly formed vessels are still present in the iris and iridocorneal angle. This review focuses on the pathology and diagnosis of neovascula glaucoma and the effect of intravitreal bevacizumab on the iris and iridocorneal angle neovascularization.
authors.affiliation: Department of Ophthalmology, School of Medicine,University of Occupational and Environmental Health, Japan.
authors.forename: Shingo
authors.initials: S
authors.lastname: Ishibashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kondo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects; D003315:Cornea / Q000098:blood supply*; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D006801:Humans; D058449:Intravitreal Injections; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab